Too Much of a Good Thing? Impact of Initial Prescription Size in Post-cesarean Section Pain Management
Impact of Reduced Initial Prescription Size on Opioid Consumption in Postoperative Pain Management for Scheduled Cesarean Deliveries
調査の概要
詳細な説明
All faculty scheduled cesarean deliveries will be eligible for possible enrollment. Once patients are scheduled for delivery, their providers will grant permission for potential participation in the study. Two weeks prior to surgery, potential participants will receive a phone call to assess interest and eligibility for participation. During the phone call, investigators will explain the goals of this research project and the overall study design. If an individual expresses interest in participation during this initial phone call, investigators will administer an intake survey. The intake survey is designed to collect data on participant eligibility as well as preexisting attitudes and experiences that may influence postoperative opioid consumption.
Patients who complete the initial survey will be approached by a member of the research team on postoperative day two or three prior to discharge from the hospital. At this time, investigators will obtain informed consent and provide each participant with an enrollment packet prepared by the principal investigator. The enrollment packet will contain educational components including information about opioids with specific instructions about how to use opioids for pain management and instructions on proper disposal of unused tablets. Investigators will also include information about alternative forms of analgesia (ibuprofen and acetaminophen) with FDA approved instructions regarding their use in pain management. The study team's goal in including these educational components for each study group is to ensure that women are able to make safe and informed decisions regarding both forms of medication for optimal pain management. The enrollment packet will also include copies of all surveys the participants will be completing and a visual representation of the numerical pain scale for participants to reference.
Women in the study will be randomized to receive either 10 or 20 tablets of oxycodone 5 mg upon discharge. Randomization of prescription groups will be achieved using a computer randomized sequence assigning participants in a 1:1 ratio to either a standard discharge prescription size (20 tablets oxycodone 5mg) or a reduced initial prescription size (10 tablets oxycodone 5 mg). Participants will not be given information regarding prescription size of other participants in the study, and will therefore be blinded as to whether or not their prescription size represents the larger or smaller group.In the event that a participant should require more opioid tablets for pain medication, there will be an option to request a refill from a designated provider. Refills across both groups will be standardized to a size of 5 tablets and healthcare providers will be notified of the participant's request in order to help determine if an earlier postoperative visit is needed for evaluation.
Outcome metrics will be collected at 3 different postoperative time points. The initial "inpatient survey" will be completed in person at the time of consent on postoperative day two or three. This survey is designed to collect information about each participant's perceived pain experience during inpatient stay and capture pain rating at time of discharge. Outcome metrics at two subsequent time points (10-14 days post-op and 6 weeks post-op) will be collected using an "outpatient survey." Participants will be given the option to complete the outpatient surveys over the phone with the investigator directly inputting metrics or through an online survey directly linked to the study electronic database. Follow-up surveys will assess a number of outcome metrics related to opioid use, participant's pain experience, and participant satisfaction with pain management.
研究の種類
入学 (予想される)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Robyn N Goodrich, BA
- 電話番号:434-825-7630
- メール:rgoodrich@vt.edu
研究連絡先のバックアップ
- 名前:Jaclyn D Nunziato, MD
- 電話番号:540-655-0459
- メール:jdnunziato@carilionclinic.org
研究場所
-
-
Virginia
-
Roanoke、Virginia、アメリカ、24014
- 募集
- Carilion Roanoke Memorial Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female
- Age 19-40 years old
- Pregnant
- Scheduled to undergo cesarean section at Carilion Roanoke Memorial Hospital
- opioid naïve (defined as no opioid use within 30 days of surgery
Exclusion Criteria:
- History of chronic pain
- History of opioid use disorder
- History of any known intolerance or allergies to analgesics
- Women with postoperative complications (hysterectomy during or after birth, bowel or bladder injury during birth, need for re-operation, or immediate wound complication)
- Language barrier preventing screening or consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:10 tablet prescription group
These participants receive 10 tablets of oxycodone 5 mg at discharge for postoperative pain.
|
Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
他の名前:
|
|
アクティブコンパレータ:20 tablet prescription group
These participants receive 20 tablets of oxycodone 5 mg at discharge for postoperative pain.
|
Reduced initial prescription of oxycodone for postoperative pain management following cesarean section.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total opioid consumption by participants post-cesarean delivery
時間枠:2 weeks
|
Number of tablets of oxycodone consumed for postoperative pain management.
This will be measured by a pill count at the participant's 2 week post-op visit and the participant's responses to postoperative surveys at 2 weeks and 6 weeks post surgery.
|
2 weeks
|
|
Total opioid consumption by participants post-cesarean delivery
時間枠:6 weeks
|
Number of tablets of oxycodone consumed for postoperative pain management.
This will be measured by a pill count at the participant's 2 week post-op visit and the participant's responses to postoperative surveys at 2 weeks and 6 weeks post surgery.
|
6 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participant pain rating
時間枠:2 weeks
|
reported level pain based on Numeric Pain Rating Scale (NPRS) 0-10, with 0 being no pain and 10 being the worst pain imaginable
|
2 weeks
|
|
Participant pain rating
時間枠:6 weeks
|
reported level pain based on Numeric Pain Rating Scale (NPRS) 0-10, with 0 being no pain and 10 being the worst pain imaginable
|
6 weeks
|
|
Participant satisfaction with pain management
時間枠:2 weeks
|
Patient reported satisfaction with postoperative pain management on survey based on opinion of whether medications provided were strong enough and the quantity of medication provided Participants are asked "were you overall satisfied with your pain management since surgery" and answer yes or no
|
2 weeks
|
|
Participant satisfaction with pain management
時間枠:6 weeks
|
Patient reported satisfaction with postoperative pain management on survey based on opinion of whether medications provided were strong enough and the quantity of medication provided Participants are asked "were you overall satisfied with your pain management since surgery" and answer yes or no
|
6 weeks
|
|
Requests for opioid prescription refills by participants
時間枠:2 weeks
|
Number of opioid refills required by participant requesting additional medication up to 6 weeks post operative
|
2 weeks
|
|
Requests for opioid prescription refills by participants
時間枠:6 weeks
|
Number of opioid refills required by participant requesting additional medication up to 6 weeks post operative
|
6 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Jaclyn D Nunziato, MD、Carilion Clinic
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 19-516
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
術後の痛みの臨床試験
-
Loughborough UniversityFitoplancton Marino, S.L.完了
-
Bingol UniversityAtaturk Universityまだ募集していません術前不安 | 恐れ | PAİN
-
Novartis Pharmaceuticals募集原発性骨髄線維症 (PMF) | 多血症後 真性骨髄線維症 (Post-PV MF) | 本態性血小板血症後骨髄線維症 (Post-ET MF)日本
-
Dexa Medica Group完了
-
GlaxoSmithKline積極的、募集していない新生物 | 原発性骨髄線維症 | 原発性骨髄線維症 (PMF) | 多血症後 真性骨髄線維症 (Post-PV MF) | 本態性血小板血症後骨髄線維症 (Post-ET MF)アメリカ, 台湾, イタリア, スペイン, ベルギー, カナダ, オーストラリア, イスラエル, シンガポール, デンマーク, ハンガリー, ルーマニア, イギリス, ブルガリア, オーストリア, フランス, ドイツ, ポーランド, オランダ, 韓国
-
Kartos Therapeutics, Inc.募集原発性骨髄線維症 (PMF) | 真性多血症後の MF (Post-PV-MF) | 本態性血小板血症後の MF (Post-ET-MF)アメリカ, 大韓民国, ドイツ, オーストラリア, ハンガリー, フランス, スペイン, イタリア, 台湾, タイ, ブラジル, ポーランド, 七面鳥, イスラエル, ポルトガル, ルーマニア, アルゼンチン, ブルガリア, カナダ, クロアチア, チェコ, リトアニア, メキシコ, フィリピン, イギリス, 香港, ロシア連邦, ギリシャ
-
Suzhou Zelgen Biopharmaceuticals Co.,Ltd完了原発性骨髄線維症 (PMF) | 真性骨髄線維症(Post-PV MF) | 本態性血小板血症後骨髄線維症(Post-ET MF)中国
-
Academisch Medisch Centrum - Universiteit van Amsterdam...募集
-
Samus Therapeutics, Inc.終了しました原発性骨髄線維症 (PMF) | 多血症後の真性骨髄線維症 (Post-PV MF) | 本態性血小板血症後骨髄線維症(ET MF後)アメリカ
Oxycodone oral capsuleの臨床試験
-
Bin CaoBeijing Chest Hospital; China-Japan Friendship Hospital; Shanghai Pulmonary Hospital, Shanghai... と他の協力者募集
-
University of Illinois at Chicago募集蛋白尿 | 鎌状赤血球貧血 (HbSS、または HbSβ-サラセミア0)アメリカ
-
Guangdong Hengrui Pharmaceutical Co., Ltd募集
-
Blekinge Institute of Technologyまだ募集していません
-
Amar h ZiregSelf funded完了